文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

应用TEG-血小板图算法指导成人轻型至中型创伤性脑损伤患者抗血小板药物逆转:一项观察性先导研究

Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study.
PubMed 文献 · Neurocrit Care · 2022-06-16
一句话结论在伤前使用抗血小板药的出血性创伤性脑损伤患者中,该研究提示基于血栓弹力图血小板图的算法可能减少血小板输注,且未伴随临床显著的血肿扩大。

该单中心观察性先导研究纳入2016年3月至2019年12月期间收治的175例创伤性脑损伤患者,其中54例为干预前对照,121例为TEG-血小板图(TEG-PM)组。经排除后,TEG-PM组62例、对照组37例。干预措施为:对存在花生四烯酸或二磷酸腺苷受体位点显著抑制的非手术患者给予去氨加压素(DDAVP);对存在显著抑制的手术患者采用DDAVP联合血小板输注的双重治疗。结果显示,对照组57%输注血小板,TEG-PM组为10%(p<0.001);干预组52%接受DDAVP,对照组为0%。两组血肿扩大体积无显著差异(TEG-PM组14.0 cm³ vs 对照组13.6 cm³,p=0.93)。

要点

  • 在伤前使用抗血小板药的出血性创伤性脑损伤患者中,TEG-PM算法组血小板输注率为10%,显著低于对照组的57%(p<0.001)。
  • TEG-PM组与对照组血肿扩大体积无显著差异(14.0 cm³ vs 13.6 cm³,p=0.93)。
  • TEG-PM组52%的患者接受了DDAVP治疗,而对照组为0%。
  • 两组在临床恶化、延迟神经外科干预或晚期血小板输注率方面均无显著差异。
  • 作者认为该算法可能减少血小板输注而不增加临床显著的血肿扩大,但需进一步研究证实因果关系。

适用人群与场景

  • 成人出血性创伤性脑损伤患者,伤前使用抗血小板药物;研究在美国一所大学附属一级创伤中心进行,纳入2016年3月至2019年12月连续收治的175例患者,排除接受抗凝药物、缺乏神经影像学资料或需急诊神经外科手术者。

诊断标准与关键阈值

  • 采用血栓弹力图血小板图(TEG-PM)检测,以花生四烯酸或二磷酸腺苷受体位点存在显著抑制作为启动干预的标准。

处置流程与药物剂量

  • 非手术患者若TEG-PM提示花生四烯酸或二磷酸腺苷受体位点显著抑制,给予去氨加压素(DDAVP)。
  • 手术患者若TEG-PM提示显著抑制,采用DDAVP联合血小板输注的双重治疗。

研究设计与关键结果

  • 研究为观察性先导研究,纳入175例连续创伤性脑损伤患者,其中干预前对照54例、TEG-PM组121例;排除后TEG-PM组62例、对照组37例。
  • TEG-PM组中位年龄75岁(四分位距85-67),对照组77岁(四分位距81-65)。
  • 入院血肿体积两组相似:TEG-PM组10.7 cm³(20.1)vs 对照组14.1 cm³(19.7),p=0.41。
  • 血小板输注率:对照组57% vs TEG-PM组10%,p<0.001。
  • DDAVP使用率:TEG-PM组52% vs 对照组0%。
  • 血肿扩大体积:TEG-PM组14.0 cm³(20.2)vs 对照组13.6 cm³(23.7),p=0.93。
  • 两组临床恶化、延迟神经外科干预或晚期血小板输注率均无显著差异。

证据类型、等级与局限

  • 证据类型:观察性先导研究,使用历史对照。
  • 研究局限:单中心、样本量有限、采用历史对照,作者指出需进一步研究以证实因果关系。

对床旁实践的改变

  • 对于伤前使用抗血小板药的出血性创伤性脑损伤患者,作者认为基于TEG-PM的算法可能减少血小板输注,而不增加临床显著的血肿扩大;该结论来自观察性研究,作者指出需进一步研究证实因果关系。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic intracranial hemorrhages expand in one third of cases, and antiplatelet medications may exacerbate hematoma expansion. However, the reversal of an antiplatelet effect with platelet transfusion has been associated with harm. We sought to determine whether a thromboelastography platelet mapping (TEG-PM)-guided algorithm could limit platelet transfusion in patients with hemorrhagic traumatic brain injury (TBI) prescribed antiplatelet medications without a resultant clinically significant increase in hemorrhage volume, late hemostatic treatments, or delayed operative intervention.

METHODS: A total of 175 consecutive patients with TBI were admitted to our university-affiliated, level I trauma center between March 2016 and December 2019: 54 preintervention patients (control) and 121 patients with TEG-PM (study). After exclusion for anticoagulant administration, availability of neuroimaging and emergent neurosurgery, 62 study patients and 37 control patients remained. Intervention consisted of administration of desmopressin (DDAVP) for nonsurgical patients with significant inhibition at the arachidonic acid or adenosine diphosphate receptor sites. For surgical patients with significant inhibition, dual therapy with DDAVP and platelet transfusion was employed. Study patients were compared with a group of historical controls, which were identified from a prospectively maintained registry and typically treated with empiric platelet transfusion.

RESULTS: Median age was 75 years (interquartile range 85-67) and 77 years (interquartile range 81-65) in the TEG-PM and control patient groups, respectively. Admission hemorrhage volumes were similar (10.7 cm3 [20.1] in patients with TEG-PM vs. 14.1 cm3 [19.7] in controls; p = 0.41). There were no significant differences in admission Glasgow Coma Scale, mechanism of trauma, or baseline comorbidities. A total of 57% of controls versus 10% of patients with TEG-PM (p < 0.001) were transfused platelets; 52% of intervention patients and 0% controls were treated with DDAVP. Expansion hemorrhage volumes were not significantly different (14.0 cm3 [20.2] patients with TEG-PM versus 13.6 cm3 [23.7] controls; p = 0.93). There was no significant difference in rates of clinical deterioration, delayed neurosurgical intervention, or late platelet transfusion between groups.

CONCLUSIONS: Among patients with hemorrhagic TBI prescribed preinjury antiplatelet therapy, our study suggests that the use of a TEG-PM algorithm may reduce platelet transfusions without a concurrent increase in clinically significant hematoma expansion. Further study is required to prove a causative relationship.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kvint S, Gutierrez A, Venezia A, et al. Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study. Neurocrit Care. 2022. PMID: 35705826. doi:10.1007/s12028-022-01535-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。